Depression is becoming the second biggest killer after cancer, with about one in five people experiencing a depressive episode at some point in their lives. As a highly disabling disease, depression has become a major public health problem in China. It is estimated that in 2020-2030, depression will become the second largest disease after cardiovascular disease.

The 12-month prevalence of depression varies widely from country to country, but is about 6% overall, and the lifetime prevalence is 15-18%. According to the report of the World Health Organization, depression is currently the fourth largest burden of disease in the world and one of the main causes of functional disability in patients. About 14.29% of people will suffer from depression at some stage in their lives. In China, however, the rate of depression recognition is only 30 percent, and the rate of hospitalization is even lower, at 10 percent.

As the understanding of depression has escalated, so has the development of antidepressants. From the early attention to the improvement of emotional symptoms of depression, to the later improvement of emotional and physical symptoms, to help patients to achieve clinical cure; A new era of antidepressant therapy is needed, guided by the therapeutic goals of overall symptom improvement and social recovery.

In response to the growing need for treatment of depression, SanCare's new combination inhaler for the treatment of depression will provide patients with more treatment options.